StonvexLoading…
StonvexStonvexStonvexCore line items from NSTS's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.
| Metric | Annual 2025 2025-12-31 | Annual 2024 2024-12-31 | Annual 2023 2023-12-31 | Annual 2022 2022-12-31 |
|---|---|---|---|---|
Revenue | $252.00K | $256.00K | $270.00K | $291.00K |
Operating Income | $-386.00K | $-789.00K | $-2.96M | $173.00K |
Net Income | $-386.00K | $-789.00K | $-3.96M | $27.00K |
EPS (Diluted) | $-0.08 | $-0.16 | $-0.79 | $0.01 |
Total Assets | $266.65M | $278.69M | $256.78M | $264.21M |
Total Liabilities | $186.67M | $202.20M | $179.23M | $183.66M |
Cash & Equivalents | $34.04M | $53.48M | $31.39M | $13.15M |
Free Cash Flow OCF − CapEx | $3.95M | $9.11M | $-85.00K | $2.77M |
Shares Outstanding | 5.26M | 5.25M | 5.32M | 5.40M |